To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company, based in a 9,000 ...
Though the coronavirus pandemic initially depressed sales, with lab closures early in 2020 and uncertainty on academic research funding, Bio-Techne has also seen some upside. The firm offers direct-to ...
Aug 7 (Reuters) - Bio-Techne (TECH.O), opens new tab reported fourth-quarter profit in line with estimates on Wednesday as growth in the diagnostics and genomics unit offset weakness in its protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results